Still Bioneer, Now even Faster
We’re excited to share that Bioneer has acquired the newest version of the Ambr®250 high-throughput bioreactor system.
With this powerful addition, we can accelerate upstream process development while maintaining the same scientific depth and quality you know us for.
Our scientists explain the impact
Hear from Christian Müller, PhD, Sr. Project Manager & Principal Scientist, and Alexandra Baer, PhD, R&D Manager, Mammalian Cell Line Development, as they explain how the Ambr® 250 enhances upstream development and de-risks scale-up for biologics production.
For biotech and pharma partners, this means:
Faster timelines – automation speeds up workflows and delivers decision-ready data sooner.
Lower risk – robust, scalable processes that translate reliably to GMP production.
No big investment – access advanced automation and expert-driven optimization without in-house setup costs.
High-throughput and automated bioprocessing – including perfusion and intensified fed-batch processes with advanced online monitoring such as CO₂ sensors.
Why choose us as partners?
- 40 years of scientific expertise
Serving the life science industry since 1982, our solutions are built on decades of hands-on research and peer-reviewed scientific contributions. - Tailored and flexible solutions
Our modular project design features clear Go/No-Go decision points and fully customized processes — tailored to your specific protein, expression system, and project goals. - Human-first approach
We believe in close collaboration, personal relationships, and building trust that lasts.
Let’s discuss your upcoming project
Fill out the form and we’ll reach out quickly for a no-strings-attached chat on how our Ambr 250 capabilities can accelerate your development.
